Healthcare

Mesoblast Limited (ASX:MSB) develops cell-based therapies for serious inflammatory conditions and markets RYONCIL in the United States. For the September 2026 quarter, the company reported preliminary RYONCIL net revenue of US$28m and a lower operating cash outflow. Its quarterly disclosure also detailed the status …

Patrys Limited (ASX:PAB) is a biotechnology company developing a clinical-stage reformulation programme and an antibody technology portfolio. After completion of dosing and follow-up for the first four participants in its RLS-2202 Phase 1a trial, the safety committee recommended progressing to a second cohort. The …

PYC Therapeutics Limited (ASX:PYC) develops RNA-based medicines for genetic diseases. Its September 2026 activities update reported higher-dose treatment in its polycystic kidney disease study and the opening of an extension stage. The company also detailed A$655m of cash and treasury investments, a figure substantially …

Cyclopharm Limited (ASX:CYC) has released an investor presentation covering the nine months to 30 September 2026, focusing on the US rollout of Technegas, its lung ventilation imaging agent. The update outlined revenue growth, an expanding installed base, developments in clinical guidelines and the company's …

Tetratherix Limited (ASX:TTX) has announced the completion of a ten-week preclinical validation study assessing TegenEOS as a carrier for platelet-rich plasma (PRP) in tendon repair. The study explores a new orthopaedic application for TegenEOS, the company's bone graft carrier built on its Tetramatrix™ platform, …

Emyria Limited (ASX:EMD) has released its quarterly activities and cash flow report for the period ended 30 September 2026. The company described the quarter as one of operational execution, highlighted by the opening of its first New South Wales clinic, growing revenue and progress …

Ceretas Limited (ASX:CTS) has enrolled the first patient in its Phase 2 CERE-CALM clinical trial. The study is evaluating the company's non-invasive therapeutic ultrasound platform as a treatment for behavioural and psychological symptoms of dementia (BPSD) in people with Alzheimer's disease.